Effect of Cranberry Extract on the Urinary System

February 18, 2022 updated by: Oya Guven, MD, Kırklareli University

Effects of Use of Cranberry Extract Instead of Antibiotics During Uncomplicated Urinary Tract Infection

In this study, we will try to emphasize the effects of using cranberry tablets, which is an alternative to antibiotic therapy, during uncomplicated urinary tract infections (only urinary tract, bladder and kidney infections did not).

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This study was Istanbul Kartal Dr. Lütfi Kırdar Training and Research Hospital Emergency Medicine Clinic and Kırklareli Training and Research Hospital Emergency Service and Internal Medicine Polyclinic. Our study; includes patients who applied to the Emergency Department and Internal Medicine outpatient clinic with the complaint of dysuria and had normal WBC, CRP, urea, and creatinine values in their analysis, and leukocyturia was found in the urine test. Two options were offered in the treatment to these patients. Vaccinium Macrocarpon Aiton preparation or fosfomycin was given for seven days. The patients were asked whether their complaints had decreased according to the Lykert-Type verbal scale at the time of admission and on the first, third, and seventh days. When the treatment was finished, leukocytes were checked in the urinalysis. This outcome was compared between the 2 treatment options. We also noted whether nausea.

Study Type

Observational

Enrollment (Actual)

2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
    • Center
      • Kirklareli, Center, Turkey, 39000
        • Oya Guven, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Among the patients who were eligible criteria, the study was terminated when the number of patients in both groups reached 80.

Description

Inclusion Criteria:

  • Older than 18
  • who have urinary tract inflammation
  • who haven't kidney dissease previous

Exclusion Criteria:

  • Younger than 18
  • Who have kidney inflammation
  • Pregnant patients
  • Who have blood test abnormal (WBC, Ure, Creatin, CRP high level)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
using fosfomycin
The patients in this group; have been prescribed fosfomycin for 7 days (3 doses, two days apart).
Drug: Fosfomycin
In this group with urinary tract inflammation; Fosfomycin was prescribed for 7 days (3 doses, 2 days apart). There are 80 patients in total.
Other Names:
  • monurol
using cranberry extract
The patients in this group; took 7 days (1 tablet each day) of cranberry tablets.
Dietary supplement: Cranberry
In this group with urinary tract inflammation; 7 days (used every day) cranberry tablet was given. There are 80 patients in total.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Treatment time
Time Frame: 7 days
After 7 days of treatment, the 2 treatment options were compared with each other.
7 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Kırklareli University

Investigators

  • Study Director: Oya Guven, Kırklareli University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 26, 2022

Primary Completion (Actual)

February 18, 2022

Study Completion (Actual)

February 18, 2022

Study Registration Dates

First Submitted

February 18, 2022

First Submitted That Met QC Criteria

February 18, 2022

First Posted (Actual)

March 2, 2022

Study Record Updates

Last Update Posted (Actual)

March 2, 2022

Last Update Submitted That Met QC Criteria

February 18, 2022

Last Verified

February 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Kırklareli University

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

IPD Plan Description

The data results of the patients will be described in the article.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cystitis

Clinical Trials on Fosfomycin

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe